• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Merck, Avillion ink development deal for nanobody psoriasis treatment

March 30, 2017 By Sarah Faulkner

Merck, Avillion ink development deal for nanobody psoriasis treatmentMerck KGaA and Avillion inked a clinical co-development deal today for Merck’s anti IL-17 A/F Nanobody therapy for plaque psoriasis. The financial terms of the deal were not disclosed.

The investigational treatment underwent Phase I development and the group plans to initiate Phase II trials this year. According to the terms of the agreement, Avillion is responsible for bringing the nanobody treatment from Phase II to Phase III and financing the clinical program through to regulatory submission.

“We are delighted to embark on this new clinical co-development project with Merck and its innovative nanobody candidate,” Avillion CEO Dr. Allison Jeynes-Ellis said in prepared remarks. “This agreement is a further endorsement of our innovative business model and follows the success of our Phase III program with Pfizer for Bosulif (bosutinib) in chronic myeloid leukaemia. We are very encouraged that our collaborative approach to advancing the development of clinical candidates and boosting our partners’ R&D productivity is gaining such awareness in the biopharma industry.”

Merck’s Anti IL-17 A/F Nanobody is a nanobody with an extended half-life – in other words, it’s designed to be effective for a longer period of time. The therapy targets cytokines IL-17A and IL-17F to treat inflammatory diseases. The nanobodies are small and have a unique structure, the companies said, and could potentially act as the foundation for “a new generation of novel biological drugs.”

Merk inked a global development and commercialization deal with Ablynx in 2013 to acquire exclusive rights to the anti IL-17 A/F Nanobody.

“The collaboration announced today with Avillion will allow us to optimally deliver on the potential of IL-17, a compound which could address several areas of unmet need for patients today,” Merck executive board member Belén Garijo added. “In parallel, we have several highly-promising priority clinical assets in our pipeline, all of which we must continue to drive in-house. By partnering appropriately, not only can we maintain the internal focus on our R&D innovation strategy, but also maximize other opportunities that emerge from our pipeline.”

Filed Under: Clinical Trials, Featured, Wall Street Beat Tagged With: Avillion, Merck

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS